Requirements for generic anti-epileptic medicines: a regulatory perspective

Por Maliepaard, Marc, Hekster, Yechiel A., Kappelle, Arnoud, van Puijenbroek, Eugène P., Elferink, André J., Welink, Jan, Gispen-de Wied, Christine C., Lekkerkerker, Frits J. F.
Publicado em 2009

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

Por van den Bemt, Bart JF, den Broeder, Alfons A, Wolbink, GJ, Hekster, Yechiel A, van Riel, Piet LCM, Benraad, Bart, van den Hoogen, Frank HJ
Publicado em 2011

Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials

Por Vrinten, Charlotte, Lipka, Alexander F, van Zwet, Erik W, Schimmel, Kirsten J M, Cornel, Martina C, Kuijpers, Marja R, Hekster, Yechiel A, Weinreich, Stephanie S, Verschuuren, Jan J G M
Publicado no BMJ Open (2015)

International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma

Por Aarnoutse, Rob E., Verweij-van Wissen, Corrien P. W. G. M., van Ewijk-Beneken Kolmer, Eleonora W. J., Wuis, Eveline W., Koopmans, Peter P., Hekster, Yechiel A., Burger, David M.
Publicado em 2002

Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis

Por Weinreich, Stephanie S., Vrinten, Charlotte, Kuijpers, Marja R., Lipka, Alexander F., Schimmel, Kirsten J. M., van Zwet, Erik W., Gispen-de Wied, Christine, Hekster, Yechiel A., Verschuuren, Jan J. G. M., Cornel, Martina C.
Publicado no Orphanet J Rare Dis (2017)

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis

Por van den Bemt, Bart J F, den Broeder, Alfons A, Wolbink, Gert-Jan, van den Maas, Aatke, Hekster, Yechiel A, van Riel, Piet L C M, Benraad, H Bart, van den Hoogen, Frank H J
Publicado em 2013